TC6-D3

C57BL/6 (female, 6 to 8 weeks old, MC38-CCR7 (GFP) cell footpad injection-induced popliteal lymph node metastasis model)^[1]

2 mg/kg; 6 mg/kg

i.p.; daily; 14 days

Slowed primary tumor growth at 2 mg/kg, with more prominent anti-tumor activity observed at 6 mg/kg; tumor weight followed the same trend.
Significantly inhibited popliteal lymph node metastasis at 6 mg/kg, as measured by IVIS imaging and reduced frequencies of CCR7⁺GFP⁺ tumor cells in popliteal lymph nodes via flow cytometry; no significant effect on inguinal lymph node metastasis was observed at either dose.
Showed no significant change in body weight compared to controls.
Significantly increased the frequency of intratumoral CD8⁺ T cells to 35.3% of CD45⁺ cells (vs. 12.1% in controls) and intratumoral IFN-γ-secreting CD8⁺ T cells to 9.66% (vs. 4.73% in controls) at 6 mg/kg; caused a smaller increase in these populations at 2 mg/kg.
Increased the frequency of IFN-γ-secreting CD8⁺ T cells in popliteal lymph nodes to 2.37% (vs. 0.92% in controls) and inguinal lymph nodes to 3.94% (vs. 2.26% in controls) at 6 mg/kg; both doses showed this effect.
Caused no significant changes in the frequency of total DCs or CCR7⁺ DCs in primary tumors, popliteal lymph nodes, or inguinal lymph nodes.
Maintained serum ALT, AST, BUN, and CREA levels within normal ranges, and showed no abnormalities in histopathology of major organs.